A phase II study of TAS-102 and Ramucirumab
Phase 2
Completed
- Conditions
- nresectable, advanced or recurrent
- Registration Number
- JPRN-jRCT2080224529
- Lead Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- completed
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
1. Has provided written informed consent
2. 20 years and over of age on the day of signing informed consent
3. Has histologically confirmed unresectable, advanced or recurrent gastric cancer
4. Is able to take medications orally
5. Is ECOG PS 0 or 1
6. Has negative pregnancy test
7. Has adequate organ function value
8. Is willing and able to comply with scheduled visits, treatment plans, laboratory tests, and other protocol procedures
Exclusion Criteria
1. Had previously received TAS-102
2. Is pregnant or breast-feeding
3. Is inappropriate for enrolment into this study in the investigator's judgment
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method